secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001628280-26-015155
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TriSalus Q4 revenue $13.2M (+60% YoY); reaffirms 2026 revenue guidance $60-62M
------------------------------------------------------------------------------

- Full-year 2025 revenue $45.2M (+53% YoY); Q4 gross margin 86.7% vs 85.3% prior year.
- Adjusted EBITDA loss improved to $0.9M in Q4 2025 from $5.7M loss in Q4 2024.
- Net loss attributable to common shareholders FY2025 $69.7M ($1.84 loss per share) vs $33.2M ($1.31) prior year.
- Raised $46M gross proceeds from public offering post-Q4; cash and equivalents $20.4M at Dec 31, 2025.
- Appointed Michael Stansky to board in Feb 2026; launched TriNav XP infusion system.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000162828026015155/0001628280-26-015155-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000162828026015155/tlsi-20260305.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-015155

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer